ArticleFrontiers in medicine2026
Case Report: Prostatic infarction mimicking prostate cancer in a patient with markedly elevated prostate-specific antigen.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostatic infarction is an uncommon benign ischemic lesion that may closely mimic prostate cancer through marked prostate-specific antigen (PSA) elevation and focal prostate abnormalities. A 69-year-old man with long-standing hypertension presented with progressive lower urinary tract symptoms and urinary retention. Pre-catheterization postvoid residual urine volume was approximately 430 mL. Total PSA was 31.858 ng/mL, free PSA was 1.291 ng/mL, and the free-to-total PSA ratio was 0.04. Magnetic resonance imaging revealed a well-circumscribed left transition-zone nodule with a Prostate Imaging Reporting and Data System (PI-RADS) score of 1, whereas contrast-enhanced ultrasound demonstrated a focal perfusion defect. Transperineal systematic biopsy with CEUS-guided targeted sampling and subsequent transurethral resection confirmed focal prostatic infarction with benign prostatic hyperplasia and basal cell hyperplasia, without adenocarcinoma. PSA decreased to 2.34 ng/mL at 1 month, remained low at 2.45 ng/mL at 3 months, and was 1.234 ng/mL approximately 16 months after TURP. This case highlights that prostatic infarction, although uncommon, may contribute to marked PSA elevation and mimic prostate cancer. In patients with high PSA levels and discordant biochemical and imaging findings, prostatic infarction should be considered as a benign differential diagnosis alongside BPH, prostatitis, prostatic abscess, and other non-malignant causes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.